NCT05661357View on ClinicalTrials.gov

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
HER2Colorectal Cancer
Interventions
DRUG

Disitamab Vedotin Combined With Fruquintinib

Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)

Trial Locations (1)

430071

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
collaborator

Huangshi Central Hospital

OTHER

collaborator

The First People's Hospital of Tianmen

UNKNOWN

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Hubei Cancer Hospital

OTHER

lead

Zhongnan Hospital

OTHER